Anthropic has confirmed that it operates a wet biology laboratory in the San Francisco Bay Area, marking a significant expansion of the artificial intelligence company’s work into physical life-science research. The facility allows Anthropic to conduct real-world biological experiments alongside its AI research, moving beyond the computer-based simulations and analysis that have traditionally defined its work.
The company confirmed the existence of the laboratory to TechCrunch after Reuters reported that Anthropic had quietly established a facility for physical biology experiments. Eric Kauderer-Abrams, Anthropic’s head of life sciences, told Reuters that real laboratory work remains essential for validating biological ideas generated or explored with AI models.
“We believe that to do biology, the final test is still, and will be for a while, in real lab work,” Kauderer-Abrams said, according to Reuters. He added that Anthropic is already conducting such work and that its laboratory operates in a manner broadly similar to biotechnology companies, combining internal research with work involving external partners.
Anthropic Moves Beyond Computer-Based Biology
The establishment of a physical laboratory represents a shift in how Anthropic is approaching AI and biological research.
Large language models can analyse scientific literature, reason about proteins and biological mechanisms, generate hypotheses and assist researchers with experimental planning. However, biological hypotheses ultimately need to be tested against physical systems.
Anthropic’s new facility provides a setting in which biological experiments can be conducted rather than relying exclusively on computational or “in silico” analysis. The company has not disclosed the precise experiments being conducted at the laboratory.
Anthropic has said that the laboratory’s principal focus is fundamental biology rather than drug discovery. That distinction is significant because the company already works with pharmaceutical and biotechnology companies and has positioned its AI systems as tools for scientific and drug-discovery research.
Acquisition of Coefficient Bio Strengthened Anthropic’s Biology Push
Anthropic’s move into physical biology follows a broader expansion of its life-sciences operations.
In April, the company acquired Coefficient Bio, a stealth AI biotechnology startup, in a reported deal worth approximately $400 million. The acquisition provided Anthropic with additional capabilities and expertise in applying AI to biological research.
The laboratory therefore represents another step in Anthropic’s effort to build capabilities that connect AI models with real scientific experimentation.
The company has also been developing AI applications for areas such as protein design and biomolecular modelling, reflecting its broader interest in using Claude and related systems to support scientific research.
Anthropic Launches Life Sciences Verification Program
The laboratory announcement came alongside another major development in Anthropic’s life-sciences strategy.
The company has launched its Life Sciences Verification Program, which gives vetted biology and life-science researchers access to more capable Claude models under safeguards specifically designed for biological research.
Anthropic said the programme had already onboarded dozens of organisations through an early-access phase before opening applications more broadly. The company has also introduced additional access arrangements for certain higher-risk biological research, with different levels of vetting depending on the model and type of work involved.
The initiative is intended to allow qualified researchers to use more capable AI systems for biological work while maintaining additional controls around higher-risk applications.
For Anthropic, this creates a broader ecosystem around its biology efforts: researchers can use Claude for computational work, while the company’s own laboratory provides a pathway for testing biological ideas through physical experiments.
Balancing Life-Science Expansion With Pharma Relationships
Anthropic’s entry into physical biology also comes as the company continues building relationships with major pharmaceutical companies.
The company recently announced a collaboration with Novo Nordisk focused on joint drug discovery. Anthropic also counts pharmaceutical and other large enterprises among its customers and partners.
That commercial relationship helps explain the company’s emphasis on fundamental biology rather than positioning its new laboratory as a direct pharmaceutical operation. Anthropic has previously faced criticism when products or services have been perceived as competing with businesses that are also its customers.
By concentrating the stated purpose of its laboratory on fundamental biological research, Anthropic can continue developing scientific capabilities while maintaining a distinction between its internal research programme and the commercial drug-development operations of pharmaceutical partners.
AI and the Physical Laboratory
The longer-term significance of Anthropic’s move lies in the possibility of connecting increasingly capable AI systems with physical scientific infrastructure.
An AI model can potentially assist with literature reviews, experimental design, data interpretation and biological modelling. When combined with laboratory equipment and automation, these capabilities could eventually allow portions of the research cycle to be handled through increasingly automated workflows.
Anthropic has not disclosed the extent to which its AI models currently control laboratory equipment or operate experiments autonomously. The company has instead confirmed that its AI models can be used in connection with physical experiments at the Bay Area facility.
The move also illustrates the changing role AI companies see for their models. Rather than functioning solely as software tools, frontier AI systems are increasingly being developed as research assistants capable of interacting with specialised scientific workflows.
A New Phase for AI-Driven Scientific Research
Anthropic’s wet laboratory puts the company closer to the intersection of artificial intelligence, biotechnology and experimental science.
The company has repeatedly argued that advanced AI could accelerate scientific discovery, while also acknowledging the risks associated with increasingly capable models in biological applications. Its new verification programme reflects an attempt to expand access to biological capabilities while applying additional controls to higher-risk work.
For now, Anthropic has kept details about its internal laboratory research private. What is clear is that the company is no longer limiting its biology ambitions to computer screens: it has established a physical environment where biological hypotheses can be tested through laboratory experiments.
The development could become an important component of Anthropic’s broader life-sciences strategy as it expands its research, partnerships and AI tools for biology.
Disclaimer: This report has been editorially prepared using publicly available information and official statements. Readers are advised to refer to official announcements for further details.
Author
About the Author
